LungLife AI, Inc.

THOUSAND OAKS, CA · Founded 2008 · CIK 0001445789 · Medtech · Private

AI-powered blood test for early lung cancer detection

lunglifeai.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$53M
17 Form D · Mar 2024
31 months since last filing
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,024,485
Private capital raisedForm D · SEC$1,968,783
Private capital raisedForm D · SEC$360,000
Private capital raised· 1 of 2 same dayForm D · SEC$1,966,802
Private capital raised· 2 of 2 same dayForm D · SEC$500,000
Private capital raisedForm D · SEC$1,240,780
Private capital raisedForm D · SEC$1,756,069
Private capital raisedForm D · SEC$3,284,704
Private capital raisedForm D · SEC$1,429,789
Private capital raisedForm D · SEC$1,782,845
Private capital raisedForm D · SEC$25,426,258
Private capital raisedForm D · SEC$1,756,081
Private capital raisedForm D · SEC$90,000
Private capital raisedForm D · SEC$2,844,999
Private capital raised· 1 of 2 same dayForm D · SEC$6,076,213
Private capital raised· 2 of 2 same dayForm D · SEC$1,083,905
Private capital raisedForm D · SEC$315,780
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
917Hinge Bio, Inc.—$59M
918C4 IMAGING, LLC—$6.0M
919Granite Medical, LLC——
920LungLife AI, Inc.—$53M
921BIOCHIP LABS, INC.——
922BIODTECH, INC.—$575K
923Innova Vascular, Inc.—$22M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 31 related persons
  • David AndersonDirector · Executive Officer
  • Paul AndersonDirector · Executive Officer
  • Sara BarringtonDirector · Executive Officer
  • Paul BillingsDirector
  • Scott BogartExecutive Officer
  • Andrew BotelerDirector
  • Gordon DavisDirector
  • Roy DavisDirector
  • Andre de FuscoDirector · Executive Officer
  • Andre De FuscoDirector · Executive Officer
  • Daotian FuDirector
  • Daotian Fu, Ph.DDirector
  • Andre FuscoDirector · Executive Officer
  • Andre de FuscoDirector · Executive Officer
  • Harry GellesDirector
  • Frederick GluckDirector
  • Alan HeegerDirector
  • Jeffrey KobDirector
  • Jianing LiuDirector
  • James McCulloughDirector
  • Paul MeyerExecutive Officer
  • Amit MunshiDirector
  • Paul PaganoDirector · Executive Officer
  • YuCai Peng, Ph.DDirector
  • Michael PfauExecutive Officer
  • Simon RaabDirector · Executive Officer
  • Tom Hyhongsok SohDirector
  • Tom Hyongsok SohDirector
  • Dennis StubblefieldDirector
  • Dennis StuffblefieDirector
  • Justin XiangDirector

Patents

USPTO · 0 granted of 7
  • Methods For Detecting Circulating Genetically Abnormal Cellsapplication
  • Methods For Detecting Lung Cancerapplication
  • Systems And Methods For Designing Accurate Fluorescence In-situ Hybridization Probe Detection On Microscopic Blood Cell Images Using Machine Learningapplication
  • Methods For Detecting Circulating Genetically Abnormal Cellsapplication
  • Methods For Detecting Circulating Genetically Abnormal Cellsapplication
  • Methods For Detecting Lung Cancerapplication
  • Systems And Methods For Designing Accurate Fluorescence In-situ Hybridization Probe Detection On Microscopic Blood Cell Images Using Machine Learningapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.